National and Kapodistrian University of Athens
Ο ανθρώπινος ιός της λευχαιμίας των Τ - κυττάρων HTLV I/II.: πολυκεντρική μελέτη σχετικά με την παρουσία του ιού στον αιμοδοτικό πληθυσμό και ομάδες υψηλού κινδύνου στην Ελλάδα
Abstract
dc:descriptionHuman T-cell lymphotropic virus-l/ll (HTLV-I/II) full-scale screening of blood donatios has been introduced since mid-1980s in public health authorities of Canada, Japan, USA and several European countries. In some cases, obligatory screening is restricted to new donors only. In Greece blood donors are routinely screened since 1999.We report the results of a recent survey that we have conducted between 1 997 and 2003, in six blood centres of southwestern Greece (Peloponese peninsula), where 151.407 donors' sera samples were tested In the present report the HTLV-I/II indeterminate reactivities of this blood donor population are also analysed.As well the epidemiology and the determinants of HTLV-I/II infection are not well defined among population groups in Greece, the prevalence of HTLV-I/II infection was investigated in a sample of 2,016 pregnant women, 302 multitransfused haematologic and oncologic patients, 93 thalassémie patients and 57 intravenous drug users originating from four geographic areas of Pelopenese peninsula, Greece, during 1997-2005. One recipient of HTLV-I infected blood and the relatives of a woman died from adult T-cell leukemia/lymphoma (ATTL) related to HTLV-I have also been tested.The initial screening of the serum samples was performed using a combined HTLV-I/II EIA method (Murex HTLV-I/II, Murex Diagnostics, Dartord, UK), which is a new generation assay that uses recombinant proteins and selected synthetic peptides of HTLV antigens. Western Blot (WB) (HTLV WB2.4, Genelabs Diagnostics, Singapore) and a line immunoassay (INNO-LIA HTLV-I/HTLV-II, Inogenetics, Ghent, Belgium) confirmed the sera that gave repeatedly positive results with the EIA method and were also used in order to distinguish HTLV types I and II. The interpretation of the results was made according to the protocol of the HTLV European Research Network (HERN). A WB was scored as HTLV-l-positive only when bands for the gag proteins pi 9 and p24 and the env proteins rgp21 and rgp46-l were present, while samples with reactivity to p24, rgp21, rgp46-ll were considered positive for anti- HTLV-II. Samples without reactivity in WB were interpreted as negative and all other banding patterns were defined as indeterminate. Criteria for interpreting the results of the INNO-LIA HTLV method were those recommended by the manufacturer.Positive or indeterminate samples by the two confirmatory methods were further investigated by polymerase chain reaction (PCR) technique. DNA was extracted from153peripheral blood mononuclear cells using Wizard® Genomic DNA purification kit (Promega, Madison, Wl, USA) according to the manufacturer’s instructions. The PCR was performed using primer pairs from the proviral pol and fax regions amplifying both HTLV-I and HTLV-II. For the poi region we used the primers Pol 3-4/SKI 1112 while for the tax region the primers KKpXl/KKpX213 and PCR was carried out as previously described.12 A control PCR using a ß-globin primer pair demonstrated that cellular DNA was amplified in all samples. For each PCR run, at least one positive DNA control (extracted from a known FITLV-I positive individual) and more than one negative DNA controls (extracted from HTL-seronegative blood donors) were used. Nucleotides sequencing of both strands of the 450 bps PCR amplicons derived using the primer pair Pol 3-4/SKI 1 1, were determined by an ABI Prism 377 DNA sequencer (Perkin Elmer, Applied Biosystems Division, Foster City, Calif.). Sequence similarity searches were carried out with the BLAST program at the website of the National Center of Biotechnology Information.Among the 107,302 serum samples of volunteer blood donors, 98 (0.09%) were repeatedly anti-HTLV-l/ll positive in EIA assay. Confirmation by WB revealed that 6 (6.1%) of these samples were positive for anti-HTLV-l, yielding an overall (0.0056%) seroprevalence (95% confidence interval, 0.0033 to 0.0079%), and 43 (43.9%) had an HTLV-l-seroindeterminate pattern. Confirmation by INNO-LIA showed also that the same six samples reacted against HTLV-I antigens, while only 22 (22.4%) of the remaining samples were indeterminate. Finally, 49 samples (50.0%) were negative by WB and 70 (71.4%) by INNO-LIA (Table 1). PCR analysis in the six positive samples showed that both poi and fax genes were amplified. Nucleotide analysis of their 450 bps amplicons revealed sequences of the HTLV-I genome.The 43 indeterminate samples, by either WB or INNO-LIA, were also tested by PCR but no amplicons were detected using anyone of the two sets of primers.This is the first report in a large blood donor population from various regions of southwestern Greece, which confirms the presence of HTLV-I infection in Greece. As six HTLV-I infected male donors of Greek origin were detected from blood transfusion services of one of the largest Greek regions, it could be suggested that the significant tourist industry and shipping trade might have contributed to the HTLV-I dissemination. A risk factor was present in five of the HTLV-I infected donors who had many sex partners in the previous years and had possibly sex with women from HTLV-l-endemic areas. None of the infected154donors were from HTLV-l-endemic countries or had prior transfusion. It is also remarkable that two of them were volunteers, donating several times and contributing thus to the spread of the HTLV-I infection. Therefore, it is considered that the decision of Creek Ministry of Health for obligatory blood donor screening for anti-HTLV-l/ll was necessary and it should be continued preventing the silent spread via blood transfusion. Our results differentiate remarkably from other European or Mediterranean studies where results seem uncertain on the requirement for routine screening.17·20Our study reveals the presence of HTLV-I infection in one thalassémie patient, in the recipient of the infected blood and in two of the five relatives of the woman died from ATTL, HTLV-I infection. In none of the pregnant women, multitransfused patients and intravenous drug users HTLV-I/II infection was confirmed. These data suggest that HTLV-I is present in Greece among populations at high-risk. However, they would not support the need for HTLV-I/II antenatal screening in Greece.Our results also confirms the HTLV-I sexual transmission in Greece by molecular analysis, as well the possible transmission by breast-feading. Therefore we conclude that HTLV-I virus is present in Greece many years ago and the screening for the detection of HTLV-I infection could be obligatory in all T-cells abnormalities.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2006
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tseliou, Parthenopi
- Τσέλιου, Παρθενόπη
Subjects
dc:subject × 21- Ρετροϊοί
- Αιμοδοτικός πληθυσμός
- Έγκυες γυναίκες
- Θαλασσαιμικοί πάσχοντες
- Πολυμεταγγιζόμενοι ασθενείς
- Ναρκωτικά, Χρήστες ενδοφλέβιων
- Αλυσιδωτή αντίδραση πολυμεράσης
- Human T - lymphotropic virus type I/II
- Retroviruses
- Blood donors
- Pregnant women
- Thalassemic patients
- Multitransused patients
- Intravenous drug users
- WB
- PCR
- INNO - KIA
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/22346